Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of LYC-30937-EC in ulcerative colitis
2016-003633-26Phase 2Terminated
- Sponsor
- Lycera
- Start
- Oct 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of parimifasor in autoimmune colitis, sponsored by Lycera. Primary endpoint: Safety and tolerability of LYC-30937-EC. Started Oct 2016; status: terminated.
02
Drugs
parimifasor
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-003633-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003633-26.